(Sharecast News) - Immunodiagnostics group Oncimmune Holdings said on Thursday that its EarlyCDT Lung test had been granted approval by the Ministry of Health for Aragon in Spain and will now be adopted in the University Hospital Miguel Servet in Zaragoza.
Oncimmune's Early CDT Lung blood test will be adopted by the Thoracic Surgery Unit of the University Hospital for use on solitary pulmonary nodules.
The AIM-listed group noted that the approval follows the issuing of a favourable assessment and report by the Evaluation Committee of the Aragonese Health System that found it had met the necessary criteria with regards to efficacy and safety.
Oncimmune highlighted that the approval also comes after its EarlyCDT Lung asset had been authorised for use within the Spanish Public Health Service by the Galician Health Service.
Chief executive Dr Adam M Hill said: "We are pleased with the progress being made by our Spanish distributor, Sabartech, towards the wider adoption of the EarlyCDT blood test within the Spanish public health system.
"The progress being made in Spain is mirroring the positive engagement we are experiencing with several NHS Clinical Commissioning Groups and Cancer Alliances in the UK. Overall, this is an encouraging development for the continued adoption of the EarlyCDT Lung blood test with national health systems globally. "
As of 1145 GMT, Oncimmune shares were up 3.25% at 143.0p.
Oncimmune (ONC)